ImpulseIndex

GLP-1 drugs are reshaping where Americans spend their money. ImpulseIndex tracks the reallocation: which industries are declining as impulse-driven behavior wanes, and which are growing as the population's relationship with food, alcohol, and impulse changes.

Each vertical below tracks two complementary data layers: curated research citations quantifying GLP-1 behavioral effects, and government economic data measuring actual industry performance. The research findings (from peer-reviewed studies, investment bank analysis, and institutional surveys) are the primary signal. Click any vertical to see the full data picture.

GLP-1 Adoption Pulse

Combined search volume for ozempic, wegovy, mounjaro, and more. As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

4.4M

→ +3.1% 3-mo

Data: Keywords Everywhere API • Monthly search volume aggregated across tracked terms

Filter Domains

Narrow the dashboard by domain type and impact direction. All domains shown by default.

Domain

Direction

Consumer Markets

Consumer spending categories directly affected by GLP-1 behavioral changes

Declining

Industries facing headwinds as impulse spending declines

Food Service / Fast Food

Fast food discretionary spending declining as impulse eating decreases.

3 research findings

Research Finding

+8% decline in fast food and coffee spending within 6 monthsDeclining

Cornell University

Industry Data · Updated monthly

Census MRTS

$100.1K

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

2.2M

↑ +22.4% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Alcohol Sales

Alcohol consumption falling as metabolic intervention reduces reward-seeking behavior.

3 research findings

Research Finding

+62% of GLP-1 users report reduced alcohol consumption frequencyDeclining

Morgan Stanley

Industry Data · Updated monthly

TTB Volume

$5.2K

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

450K

→ 0.0% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Growing

Industries benefiting from healthier consumer behavior

Rx / Prescription Volume

GLP-1 prescription volume accelerating as insurance coverage expands.

2 research findings

Research Finding

+364% relative increase in GLP-1 prescriptions 2019 to 2024Growing

FAIR Health

Industry Data · Updated annually

Medicare Part D Claims

$9.8M

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

4K

→ 0.0% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Sports Nutrition

Protein supplement and performance nutrition demand surging as GLP-1 users prioritize muscle preservation.

2 research findings

Research Finding

+38% increase in protein shake spending among GLP-1 householdsGrowing

Numerator

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

27K

↓ -45.3% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Cosmetic & Aesthetic

Cosmetic procedures surging as rapid weight loss creates demand for body contouring.

1 research finding

Research Finding

+54% annual growth in aesthetic procedures among GLP-1 users post-FDA approvalGrowing

Johns Hopkins / Aesthetic Surgery Journal

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

10K

↓ -18.2% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Life Insurance

Life insurers benefiting from improved mortality expectations across covered populations.

2 research findings

Research Finding

+0.5% annual mortality improvement rate attributable to GLP-1 adoption (high estimate)Growing

Munich Re

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

74K

↑ +22.3% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Monitoring

Industries showing mixed or evolving patterns

Gaming & Gambling

GLP-1 receptor modulation affects the dopamine reward pathway that underlies gambling behavior. The direction of effect is genuinely uncertain: one case report documents gambling disorder remission on semaglutide; a separate hypothesis letter argues GLP-1 may cause impulse control disorders. No clinical trials exist. ImpulseIndex tracks this as an unresolved evidence gap.

2 research findings

Research Finding

1patient case report documenting gambling disorder remission on semaglutideMonitoring

Journal of Clinical Psychopharmacology

Pending next scheduled update · AGA Commercial Gaming Revenue Tracker

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

480

↓ -52.0% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Creator Economy

GLP-1 is reallocating attention and spending within the creator economy — wellness, fitness, and food content are shifting as user behavior changes.

4 research findings

Research Finding

+43% of GLP-1 users reporting decreased food content engagementMonitoring

Harris Poll

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

1.2M

→ -0.2% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Airlines

Airlines adapting seat configurations and pricing as passenger weight distributions shift.

2 research findings

Research Finding

+26% of GLP-1 users report flying more oftenGrowing

Dentsu

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

50

→ 0.0% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Fitness Clubs & Gyms

Gym memberships evolving as fitness motivation shifts from weight loss to maintenance.

3 research findings

Research Finding

+47% of GLP-1 users report increased gym attendanceGrowing

Dentsu

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

15K

↓ -45.4% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Dating & Relationships

Dating app engagement changing as confidence and self-presentation evolve.

2 research findings

Research Finding

+70% of GLP-1 users report improved relationship qualityGrowing

Dentsu

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

442K

↓ -18.2% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Clinical Impact Domains

Healthcare categories where GLP-1 mechanisms produce documented effects beyond weight loss

Declining

Industries facing headwinds as impulse spending declines

Addiction & Rehabilitation

GLP-1 medications are reducing incident and relapse rates across multiple substance use disorders, creating structural demand contraction for the rehabilitation industry.

4 research findings

Research Finding

0.82hazard ratio for incident alcohol use disorder vs SGLT-2 inhibitorsDeclining

The BMJ

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

390

↑ +21.9% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Tobacco & Nicotine

Spontaneous nicotine cessation documented in GLP-1 users through the same reward pathway mechanism driving alcohol reduction — a headwind for tobacco manufacturers and nicotine replacement therapy markets.

2 research findings

Research Finding

0.8hazard ratio for incident nicotine use disorder vs SGLT-2 inhibitorsDeclining

The BMJ

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

30

↑ +50.0% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Growing

Industries benefiting from healthier consumer behavior

Reproductive Health & Fertility

GLP-1-driven PCOS resolution is restoring menstrual cyclicity and triggering unexpected pregnancies in previously infertile patients, driving demand across fertility services and downstream maternity categories.

1 research finding

Research Finding

+86.87% menstrual cyclicity restoration vs 60% controlGrowing

Metabolism and Target Organ Damage

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

2K

↓ -35.4% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Chronic Pain & Rheumatology

GLP-1's anti-inflammatory effects are driving documented remissions in osteoarthritis, psoriatic arthritis, and autoimmune conditions — growing demand for GLP-1 as adjunct therapy while pressuring existing biologic treatment markets.

3 research findings

Research Finding

41.7point WOMAC pain score reduction vs 27.5 points placeboGrowing

NEJM

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

2K

↑ +19.1% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Dermatology

Psoriasis, hidradenitis suppurativa, and rare blistering conditions showing remission on GLP-1 therapy — driving new patient cohorts into dermatology practices while creating headwinds for existing biologic manufacturers.

3 research findings

Research Finding

+92.2% reduction in PASI scoreGrowing

Journal of Clinical and Aesthetic Dermatology

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

350

→ +2.9% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Monitoring

Industries showing mixed or evolving patterns

Sleep Medicine

Tirzepatide reduced sleep apnea severity by up to 63 percent in SURMOUNT-OSA trials — a direct signal for CPAP manufacturers and sleep medicine practice volumes, with mixed net effects.

1 research finding

Research Finding

+63% reduction in apnea-hypopnea indexMonitoring

Eli Lilly / NEJM

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

980

↓ -47.9% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Psychiatric & Behavioral Health

Large-scale cohort data shows GLP-1 association with reduced depression, anxiety, and suicidal ideation — with implications for psychopharmaceutical markets and behavioral health practice volumes that are still evolving.

4 research findings

Research Finding

0.56adjusted hazard ratio for worsening depressionMonitoring

The Lancet Psychiatry

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

1K

↓ -18.3% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Neurology & Cognitive Health

Semaglutide associated with 40-70 percent reduced risk of first-time Alzheimer's diagnosis in Type 2 diabetes patients — an early but significant signal for the dementia care and neurology sectors.

2 research findings

Research Finding

0.33hazard ratio for Alzheimer's disease diagnosis vs insulinMonitoring

Alzheimer's & Dementia

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

150

↓ -31.8% 3-mo

Data: Keywords Everywhere API · Monthly search volume

Hepatology & Liver Disease

Tirzepatide achieved 62 percent MASH resolution versus 10 percent placebo in SYNERGY-NASH — a direct signal for the NASH therapeutics pipeline and liver transplant and hepatology procedure volumes.

1 research finding

Research Finding

+62% MASH resolution vs 10% placebo at 52 weeksGrowing

NEJM

Manually monitored, no automated source

Search Interest

Google search volume for related keywords. Note: As users migrate to AI tools, absolute volume may decline while relative trends remain meaningful.

980

→ -1.0% 3-mo

Data: Keywords Everywhere API · Monthly search volume